PBAC's latest decision on Collagenase clostridium histolyticum: Not recommended (2014). Considered for Treatment of Dupuytren's contracture in patients with ≤2 affected rays (fingers) who are unable to simultaneously place the affected finger and palm flat on a table due to a Dupuytren's contracture with a palpable cord and who would otherwise require surgery.
PBAC outcome
Not recommended
Authority Required
ICER (AUD/QALY)
—
ICER not stated
Submissions
2
first 2013
Submissions
2
2013 → 2014
Eligible population
Adults with Dupuytren's contracture affecting ≤2 rays who are unable to simultaneously place the affected finger and palm flat on a table due to a palpable cord and would otherwise require surgery.
Therapy area
Other
Line of therapy
Not applicable
Evidence base
Single-arm
Primary endpoint
Other
Key trials
DUPY 303
Comparator
surgical fasciectomy
Economic model
Cost-minimisation
ICER note
Document text is incomplete; economic analysis details not provided in the excerpt.
Why PBAC said no
Reasons cited in the latest PSD: The document is truncated and does not provide the PBAC outcome or rejection reasons in the excerpt provided.
Submission history
Jul 2013: Recommended with restriction · Authority Required